232 related articles for article (PubMed ID: 10688838)
1. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Pinilla-Ibarz J; Cathcart K; Korontsvit T; Soignet S; Bocchia M; Caggiano J; Lai L; Jimenez J; Kolitz J; Scheinberg DA
Blood; 2000 Mar; 95(5):1781-7. PubMed ID: 10688838
[TBL] [Abstract][Full Text] [Related]
2. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
Cathcart K; Pinilla-Ibarz J; Korontsvit T; Schwartz J; Zakhaleva V; Papadopoulos EB; Scheinberg DA
Blood; 2004 Feb; 103(3):1037-42. PubMed ID: 14504104
[TBL] [Abstract][Full Text] [Related]
3. CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
Yasukawa M; Ohminami H; Kaneko S; Yakushijin Y; Nishimura Y; Inokuchi K; Miyakuni T; Nakao S; Kishi K; Kubonishi I; Dan K; Fujita S
Blood; 1998 Nov; 92(9):3355-61. PubMed ID: 9787173
[TBL] [Abstract][Full Text] [Related]
4. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
[TBL] [Abstract][Full Text] [Related]
5. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.
Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Roberts W; Scheinberg DA
Haematologica; 2005 Oct; 90(10):1324-32. PubMed ID: 16219568
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Sun JY; Krouse RS; Forman SJ; Senitzer D; Sniecinski I; Chatterjee S; Wong KK
Cancer Res; 2002 Jun; 62(11):3175-83. PubMed ID: 12036931
[TBL] [Abstract][Full Text] [Related]
7. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
[TBL] [Abstract][Full Text] [Related]
8. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
[TBL] [Abstract][Full Text] [Related]
9. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
[TBL] [Abstract][Full Text] [Related]
10. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
Yasukawa M; Ohminami H; Kojima K; Hato T; Hasegawa A; Takahashi T; Hirai H; Fujita S
Blood; 2001 Sep; 98(5):1498-505. PubMed ID: 11520800
[TBL] [Abstract][Full Text] [Related]
11. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
[TBL] [Abstract][Full Text] [Related]
12. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
[TBL] [Abstract][Full Text] [Related]
13. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial.
Jain N; Reuben JM; Kantarjian H; Li C; Gao H; Lee BN; Cohen EN; Ebarb T; Scheinberg DA; Cortes J
Cancer; 2009 Sep; 115(17):3924-34. PubMed ID: 19536894
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
[TBL] [Abstract][Full Text] [Related]
15. Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
He L; Feng H; Raymond A; Kreeger M; Zeng Y; Graner M; Whitesell L; Katsanis E
Cancer Immunol Immunother; 2001 Mar; 50(1):31-40. PubMed ID: 11315508
[TBL] [Abstract][Full Text] [Related]
16. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Zeng Y; Graner MW; Thompson S; Marron M; Katsanis E
Blood; 2005 Mar; 105(5):2016-22. PubMed ID: 15374884
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL fusion peptides and cytotoxic T cells in chronic myeloid leukaemia.
Clark RE; Christmas SE
Leuk Lymphoma; 2001; 42(5):871-80. PubMed ID: 11697642
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
[TBL] [Abstract][Full Text] [Related]
19. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial.
Bocchia M; Gentili S; Abruzzese E; Fanelli A; Iuliano F; Tabilio A; Amabile M; Forconi F; Gozzetti A; Raspadori D; Amadori S; Lauria F
Lancet; 2005 Feb 19-25; 365(9460):657-62. PubMed ID: 15721470
[TBL] [Abstract][Full Text] [Related]
20. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
Norbury LC; Clark RE; Christmas SE
Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
